Emergent BioSolutions reported a $191.3 million non-cash impairment charge on its NARCAN asset group, resulting in a GAAP net loss of $180.2 million for the quarter ended June 30, 2026. The company also lowered its full-year revenue guidance by about 10.8%, citing increased competition affecting its outlook and asset value. Following this announcement, Emergent's stock price plunged nearly 30%. Pomerantz LLP has launched an investigation into whether Emergent and its executives engaged in securities fraud or other unlawful practices, potentially leading to a class action lawsuit.
Emergent BioSolutions is the subject of an investor alert regarding a legal investigation. For readers following the health sector, here is Pluang's market snapshot as of Sep 17, 2026 21:11 WIB: out of 91 priced US health stocks, 59 rose and 31 fell. Notable movers include RXRX at USD 3.37 with a 5.64% increase and 100% buy order activity, ILMN at USD 241.64 with a 5.55% rise and 97% sell order activity, and DNA at USD 7.44 with a 5.38% gain.
Pepeto, a new cryptocurrency on the Ethereum network, has quickly raised over $11.23 million in its presale, with each funding stage closing faster than the last. This momentum comes as Ethereum is predicted to reach $10,000 by the end of 2026, drive...
BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...
Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...
K2 Vision has completed over 5,000 procedures using the Light Adjustable Lens (LAL), making it the highest-volume practice worldwide for this technology. The LAL is unique because it can be adjusted after implantation to fine-tune vision based on the...
BlackRock, Inc. disclosed that its shareholding in Fagron NV dropped below the 3% threshold to 2.96% after selling some voting securities, despite acquiring equivalent financial instruments. As of October 12, 2026, BlackRock holds 2,015,779 voting ri...
